ICO up coming news
?iCo Therapeutics Australia Pty Ltd. has received full payment of approximately $462,000 Australian dollars (AUD) for R&D expenditures conducted during its past fiscal year, during which the Company conducted a Phase 1 clinical study. Refundable cash tax credits at a reimbursement rate for qualified companies may be up to a maximum of 43.5% in Australia.
?iCo is reviewing quotes for its proposed Phase 2 study, which is also anticipated to be conducted in Australia. The Company is looking at funding options to support the initiation of enrollment in Q1 2019.
?iCo also announces a recent six month stability pull for its most recent batch of iCo-019 in inventory. GMP grade materials remain in storage at iCo's CMO for future clinical use.
?iCo is currently recruiting a world class group of clinical experts in the anti-fungal arena and expects to announce a clinical advisory board for oral Amphotericin B in early Q4.
?iCo now expects to present its full Phase 1 data analysis to the public in Q4 2018.
?iCo's licensee recently received Fast Track designation for iCo-008 use in bullous pemphigoid (BP) by the US Food and Drug Administration (FDA). The FDA has also recently granted orphan drug designation to iCo-008 for the treatment of bullous pemphigoid. Under this license agreement, iCo may receive up to $32M in milestone payments, beginning with a material payment upon first dose in a pivotal BP trial. iCo's licensee continues to make significant development progress and is currently planning for a pivotal clinical study for BP and expects preliminary data from its second Phase 2 study in ulcerative colitis (UC) in Q1 2019.
"these posts are not of a licensed investment advisor or analyst nor does he give out buy, sell or hold advice to anyone"
AI
